Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Aug '25 Aug 8, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Market Capitalization	103	149	121	153	-	-	Upgrade
Market Cap Growth	22.33%	22.33%	-20.82%	-	-	-	Upgrade
Enterprise Value	172	186	156	154	-	-	Upgrade
Last Close Price	2.66	3.96	3.26	4.09	-	-	Upgrade
Forward PE	-	72.00	-	32.88	-	-	Upgrade
PS Ratio	19.77	28.40	6.14	4.80	-	-	Upgrade
PB Ratio	12.47	17.91	18.85	3.47	-	-	Upgrade
P/TBV Ratio	-	-	20.38	3.49	-	-	Upgrade
EV/Sales Ratio	32.81	35.58	7.87	4.81	-	-	Upgrade
Debt / Equity Ratio	6.98	6.98	7.57	0.63	0.56	1.13	Upgrade
Debt / EBITDA Ratio	-	-	-	-	19.97	-	Upgrade
Asset Turnover	0.06	0.06	0.24	0.60	0.59	0.47	Upgrade
Inventory Turnover	-	-	0.40	0.56	0.07	0.05	Upgrade
Quick Ratio	0.23	0.23	0.32	1.19	1.25	1.30	Upgrade
Current Ratio	1.75	1.75	1.04	2.42	1.99	3.10	Upgrade
Return on Equity (ROE)	-312.71%	-312.71%	-153.29%	-52.44%	-4.80%	-6.13%	Upgrade
Return on Assets (ROA)	-6.14%	-6.14%	-22.61%	-16.56%	0.84%	-0.81%	Upgrade
Return on Capital (ROIC)	-8.25%	-8.25%	-28.98%	-20.88%	1.11%	-0.98%	Upgrade
Return on Capital Employed (ROCE)	-	-	-	-	1.80%	-	Upgrade
Earnings Yield	-22.22%	-15.47%	-31.91%	-8.94%	-	-	Upgrade
FCF Yield	-8.68%	-6.04%	-25.21%	-27.94%	-	-	Upgrade
Buyback Yield / Dilution	-4.73%	-4.73%	0.27%	-19.73%	-15.31%	-15.46%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.